Phase III STELLAR clinical study results have demonstrated that the combination of eflornithine and lomustine achieved clinically meaningful improvements in overall survival and progression-free survival compared to lomustine alone in patients with recurrent IDH mutant, grade 3 astrocytoma.
In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.
